Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in J Invest Dermatol

Retrieve available abstracts of 81 articles:
HTML format



Single Articles


    September 2021
  1. CHHABRA G, Singh CK, Guzman-Perez G, Ndiaye MA, et al
    Anti-melanoma effects of concomitant inhibition of SIRT1 and SIRT3 in Braf(V600E)/Pten(NULL) mice.
    J Invest Dermatol. 2021 Sep 28. pii: S0022-202X(21)02223.
    PubMed     Abstract available


  2. XU T, Dai J, Tang L, Yang L, et al
    EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma.
    J Invest Dermatol. 2021 Sep 24. pii: S0022-202X(21)02227.
    PubMed     Abstract available


  3. EMMONS MF, Smalley KSM
    Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01436.
    PubMed     Abstract available


  4. ADELMANN CH, Rachmin I, Fisher DE
    MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01224.
    PubMed     Abstract available


  5. GUTIERREZ-SEIJO A, Garcia-Martinez E, Barrio-Alonso C, Parra-Blanco V, et al
    Activin A sustains the metastatic phenotype of tumor associated macrophages and is a prognostic marker in human cutaneous melanoma.
    J Invest Dermatol. 2021 Sep 6. pii: S0022-202X(21)02171.
    PubMed     Abstract available


    August 2021
  6. DAS I, Tuominen R, Helleday T, Hansson J, et al
    Co-expression of MTH1 and PMS2 is associated with advanced disease and disease progression after therapy in melanoma.
    J Invest Dermatol. 2021 Aug 18. pii: S0022-202X(21)01689.
    PubMed    


  7. NARDIN C, Laheurte C, Puzenat E, Boullerot L, et al
    Naturally occurring Telomerase-specific CD4 T cell Immunity in Melanoma.
    J Invest Dermatol. 2021 Aug 2. pii: S0022-202X(21)01667.
    PubMed     Abstract available


    July 2021
  8. MONTAUDIE H, Sormani L, Dadone-Montaudie B, Heim M, et al
    CLEC12B decreases melanoma proliferation by repressing STAT3.
    J Invest Dermatol. 2021 Jul 23. pii: S0022-202X(21)01464.
    PubMed     Abstract available


  9. QUADRI M, Comitato A, Palazzo E, Tiso N, et al
    Activation of PKG restricts melanoma growth and invasion by interfering with the EGF/EGFR pathway.
    J Invest Dermatol. 2021 Jul 12. pii: S0022-202X(21)01420.
    PubMed     Abstract available


  10. WANG S, Yi X, Wu Z, Guo S, et al
    CAMKK2 defines ferroptosis sensitivity of melanoma cells by regulating AMPK-Nrf2 pathway.
    J Invest Dermatol. 2021 Jul 6. pii: S0022-202X(21)01416.
    PubMed     Abstract available


  11. PATMANATHAN SN, Tong BT, Jackie Teo JH, Jonathan Ting YZ, et al
    A PDZ Protein GIPC3 Positively Modulates Hedgehog Signaling and Melanoma Growth.
    J Invest Dermatol. 2021 Jul 2. pii: S0022-202X(21)01414.
    PubMed     Abstract available


  12. CHU EY, Takeshita J, Ming ME
    Shedding Light on Disparities in Melanoma Care.
    J Invest Dermatol. 2021;141:1625-1626.
    PubMed     Abstract available


    June 2021
  13. SHEINBOIM D, Parikh S, Parikh R, Menuchin A, et al
    Slow transcription of the 99a/let-7c/125b-2 cluster results in differential miRNA expression and promotes melanoma phenotypic plasticity.
    J Invest Dermatol. 2021 Jun 26. pii: S0022-202X(21)01406.
    PubMed     Abstract available


    May 2021
  14. WANG H, Yi X, Guo S, Wang S, et al
    The XBP1-MARCH5-MFN2 axis confers ER stress resistance by coordinating mitochondrial fission and mitophagy in melanoma.
    J Invest Dermatol. 2021 May 25. pii: S0022-202X(21)01243.
    PubMed     Abstract available


  15. TSENG YJ, Lee CH, Chen WY, Yang JL, et al
    Inhibition of plasminogen activator inhibitor-1 blocks programmed death ligand 1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.
    J Invest Dermatol. 2021 May 14. pii: S0022-202X(21)01230.
    PubMed     Abstract available


    April 2021
  16. MUNIZ TP, Sorotsky H, Kanjanapan Y, Rose AAN, et al
    Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma.
    J Invest Dermatol. 2021 Apr 5. pii: S0022-202X(21)01132.
    PubMed     Abstract available


  17. DU-HARPUR X, Arthurs C, Ganier C, Woolf R, et al
    Clinically Relevant Vulnerabilities of Deep Machine Learning Systems for Skin Cancer Diagnosis.
    J Invest Dermatol. 2021;141:916-920.
    PubMed    


    March 2021
  18. HARBERS FN, Thier B, Stupia S, Zhu S, et al
    Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8(+) tumor-infiltrating lymphocytes.
    J Invest Dermatol. 2021 Mar 30. pii: S0022-202X(21)01124.
    PubMed     Abstract available


  19. AL EMRAN A, Tseng HY, Gunatilake D, Cook SJ, et al
    A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma.
    J Invest Dermatol. 2021 Mar 26. pii: S0022-202X(21)01121.
    PubMed     Abstract available


  20. GUHAN SM, Shaughnessy M, Rajadurai A, Taylor M, et al
    The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma.
    J Invest Dermatol. 2021 Mar 18. pii: S0022-202X(21)00977.
    PubMed     Abstract available


  21. PERES J, Damerell V, Chauhan J, Popovic A, et al
    TBX3 promotes melanoma migration by transcriptional activation of ID1 which prevents activation of E-cadherin by MITF.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01001.
    PubMed     Abstract available


  22. MARCHETTI MA, Nanda JK, Mancebo SE, Dusza SW, et al
    Real-world application of a non-invasive 2-gene expression test for melanoma diagnosis.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01018.
    PubMed    


  23. FREUND L, Kjaer SK, Guleria S, Albieri V, et al
    Use of fertility drugs and risk of malignant melanoma: results from a large Danish population-based cohort study.
    J Invest Dermatol. 2021 Mar 16. pii: S0022-202X(21)01022.
    PubMed     Abstract available


  24. TIKOO S, Jain R, Tomasetig F, On K, et al
    Amelanotic B16-F10 melanoma compatible with advanced 3-D imaging modalities.
    J Invest Dermatol. 2021 Mar 3. pii: S0022-202X(21)00156.
    PubMed    


    February 2021
  25. GRAMANN AK, Frantz WT, Dresser K, Ferreira Gomes CB, et al
    BMP signaling promotes neural crest identity and accelerates melanoma onset.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00150.
    PubMed    


  26. KIM KB, Soroceanu L, de Semir D, Millis SZ, et al
    Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00155.
    PubMed     Abstract available


  27. SCHEEREN FA, van Doorn R
    Inhibition of the Epigenetic Reader BRD4 Reduces SIRPalpha-Mediated Phagocytosis and Melanoma Invasion.
    J Invest Dermatol. 2021;141:252-254.
    PubMed     Abstract available


  28. OSTROWSKI SM, Fisher DE
    The Melanocyte Lineage Factor miR-211 Promotes BRAF(V600E) Inhibitor Resistance.
    J Invest Dermatol. 2021;141:250-252.
    PubMed     Abstract available


    January 2021
  29. SHAH P, Shao Y, Geller AC, Polsky D, et al
    Late stage melanoma in New York State: associations with socioeconomic factors and healthcare access at the county level.
    J Invest Dermatol. 2021 Jan 28. pii: S0022-202X(21)00031.
    PubMed     Abstract available


  30. YU WY, Hill ST, Chan ER, Pink JJ, et al
    Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma.
    J Invest Dermatol. 2021 Jan 5. pii: S0022-202X(20)32413.
    PubMed     Abstract available


  31. ZHOU Q, Kim SH, Perez-Lorenzo R, Liu C, et al
    Phenformin Promotes Keratinocyte Differentiation via the Calcineurin/NFAT Pathway.
    J Invest Dermatol. 2021;141:152-163.
    PubMed     Abstract available


    December 2020
  32. TRAVNICKOVA J, Patton EE
    Deciphering melanoma cell states and plasticity with zebrafish models.
    J Invest Dermatol. 2020 Dec 16. pii: S0022-202X(20)32400.
    PubMed     Abstract available


  33. FUKUMOTO T, Lin J, Fatkhutdinov N, Liu P, et al
    ARID2 deficiency correlates with the response to immune checkpoint blockade in melanoma.
    J Invest Dermatol. 2020 Dec 14. pii: S0022-202X(20)32396.
    PubMed     Abstract available


    November 2020
  34. DOEPNER M, Lee IY, Ridky TW
    Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis.
    J Invest Dermatol. 2020;140:2114-2116.
    PubMed     Abstract available


    October 2020
  35. POIZEAU F, Kerbrat S, Happe A, Rault C, et al
    Patients with metastatic melanoma receiving anticancer drugs: changes in overall survival, 2010-2017.
    J Invest Dermatol. 2020 Oct 10. pii: S0022-202X(20)32138.
    PubMed     Abstract available


    September 2020
  36. OLSEN CM, Pandeya N, Dusingize JC, Thompson BS, et al
    Can people correctly assess their future risk of melanoma?
    J Invest Dermatol. 2020 Sep 11. pii: S0022-202X(20)31964.
    PubMed    


  37. ZHANG C, Smalley I, Emmons MF, Sharma R, et al
    Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma.
    J Invest Dermatol. 2020 Sep 2. pii: S0022-202X(20)32047.
    PubMed     Abstract available


  38. CORNELIUS LA
    The Melanoma JID Connector Collection: An Introduction.
    J Invest Dermatol. 2020;140:1690.
    PubMed    


  39. LEE B, Sahoo A, Sawada J, Marchica J, et al
    MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAF(V600E)-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance.
    J Invest Dermatol. 2020 Sep 1. pii: S0022-202X(20)32043.
    PubMed     Abstract available


  40. HUANG SW, Wang ST, Chang SH, Chuang KC, et al
    Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
    J Invest Dermatol. 2020;140:1771-1783.
    PubMed     Abstract available


    August 2020
  41. SWAMINATHAN K, Campbell A, Papalazarou V, Jaber-Hijazi F, et al
    The RAC1 target NCKAP1 plays a crucial role in progression of BRAF/PTEN -driven melanoma in mice.
    J Invest Dermatol. 2020 Aug 7. pii: S0022-202X(20)31956.
    PubMed     Abstract available


  42. RODGERS CB, Broit N, Johansson PA, Pritchard AL, et al
    Attack of the Subclones: Accurate Detection of Mutational Heterogeneity in Bulk DNA from Tumors.
    J Invest Dermatol. 2020;140:1501-1503.
    PubMed     Abstract available


  43. QUAN VL, Zhang B, Zhang Y, Mohan LS, et al
    Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
    J Invest Dermatol. 2020;140:1599-1608.
    PubMed     Abstract available


    July 2020
  44. LE K, Matar H, Gupta M
    Bromodomain epigenetic protein promotes metastatic potential in melanoma cells via increased invasiveness and decreased macrophage-mediated phagocytosis.
    J Invest Dermatol. 2020 Jul 6. pii: S0022-202X(20)31733.
    PubMed    


  45. TETZLAFF MT, Farah M
    Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms.
    J Invest Dermatol. 2020;140:1320-1323.
    PubMed     Abstract available


    June 2020
  46. WANG P, Li Y, Ma Y, Zhang X, et al
    Comprehensive investigation into the role of ubiquitin conjugating enzyme E2S (UBE2S) in melanoma development.
    J Invest Dermatol. 2020 Jun 27. pii: S0022-202X(20)31729.
    PubMed     Abstract available


  47. RAHMAN H, Kumar D, Liu T, Okwundu N, et al
    Aspirin protects melanocytes and keratinocytes against UVB-induced DNA damage in vivo.
    J Invest Dermatol. 2020 Jun 19. pii: S0022-202X(20)31684.
    PubMed     Abstract available


    May 2020
  48. TRUCCO LD, Mundra PA, Garcia-Martinez P, Hogan K, et al
    Map3k1 Loss Cooperates With Braf(V600E) to Drive Melanomagenesis.
    J Invest Dermatol. 2020 May 22. pii: S0022-202X(20)31598.
    PubMed    


  49. NGUYEN MQ, Teh JLF, Purwin TJ, Chervoneva I, et al
    Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition.
    J Invest Dermatol. 2020 May 7. pii: S0022-202X(20)31406.
    PubMed     Abstract available


  50. ADAM C, Fusi L, Weiss N, Goller SG, et al
    Efficient suppression of NRAS-driven melanoma by co-inhibition of ERK1/2 and ERK5 MAPK pathways.
    J Invest Dermatol. 2020 May 3. pii: S0022-202X(20)31407.
    PubMed     Abstract available


    April 2020
  51. AVITAN-HERSH E, Feng Y, Vaisman AO, Ahmed YA, et al
    Regulation of eIF2alpha by RNF4 promotes melanoma tumorigenesis and therapy resistance.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31404.
    PubMed     Abstract available


  52. TIFFEN J, Gallagher S, Filipp F, Gunatilake D, et al
    EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31390.
    PubMed     Abstract available


  53. CHAVEZ A, Quesenberry CP Jr, Darbinian J, Asgari MM, et al
    Association of valproic acid use, a potent histone deacetylase inhibitor, and melanoma risk.
    J Invest Dermatol. 2020 Apr 27. pii: S0022-202X(20)31402.
    PubMed     Abstract available


  54. GUO Y, Zhang X, Zeng W, Zhang J, et al
    TRAF6 activates fibroblasts to cancer-associated fibroblasts (CAFs) through FGF19 in tumor microenvironment to benefit the malignant phenotype of melanoma cells.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31352.
    PubMed     Abstract available


  55. KUNG FF, Arias-Mejias SM, Quattrocchi E, Sominidi-Damodaran S, et al
    PD-1, PD-L1 and BIM as predictors of sentinel lymph node metastasis in primary cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31349.
    PubMed    


  56. DIKA E, Riefolo M, Porcellini E, Broseghini E, et al
    Defining the prognostic role of microRNAs in cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31351.
    PubMed     Abstract available


  57. JENKINS RW, Fisher DE
    Treatment of Advanced Melanoma in 2020 and Beyond.
    J Invest Dermatol. 2020 Apr 5. pii: S0022-202X(20)31257.
    PubMed     Abstract available


  58. JOSHI SS, Hornyak TJ
    Cellular Phenotypic Plasticity of Cutaneous Melanoma: A Complex Puzzle.
    J Invest Dermatol. 2020;140:743-745.
    PubMed     Abstract available


  59. HALSE H, Caramia F, McLean CA, Wang M, et al
    A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response.
    J Invest Dermatol. 2020;140:869-877.
    PubMed     Abstract available


    March 2020
  60. CHRISTODOULOU E, Nell RJ, Verdijk RM, Gruis NA, et al
    Loss of wild-type CDKN2A is an early event in the development of melanoma in FAMMM syndrome.
    J Invest Dermatol. 2020 Mar 28. pii: S0022-202X(20)31205.
    PubMed    


  61. KIM E, Panzella L, Napolitano A, Payne GF, et al
    Redox Activities of Melanins Investigated by Electrochemical Reverse Engineering: Implications for their Roles in Oxidative Stress.
    J Invest Dermatol. 2020;140:537-543.
    PubMed     Abstract available


    February 2020
  62. VESELY MD, Chen L
    Normalization Cancer Immunotherapy for Melanoma.
    J Invest Dermatol. 2020 Feb 21. pii: S0022-202X(20)30153.
    PubMed     Abstract available


  63. CHANG GA, Wiggins JM, Corless BC, Syeda MM, et al
    TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors.
    J Invest Dermatol. 2020 Feb 19. pii: S0022-202X(20)30159.
    PubMed     Abstract available


  64. PATEL S, Wilkinson CJ, Sviderskaya EV
    Loss of both CDKN2A and CDKN2B allows for centrosome overduplication in melanoma.
    J Invest Dermatol. 2020 Feb 14. pii: S0022-202X(20)30147.
    PubMed     Abstract available


    January 2020
  65. GUO D, Jain R, Hwang JS, Weninger W, et al
    RAB27A/Melanophilin blocker inhibits melanoma cell motility and invasion.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30036.
    PubMed    


  66. LANG UE, Torres R, Cheung C, Vladar EK, et al
    Ciliation index is a useful diagnostic tool in challenging spitzoid melanocytic neoplasms.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30038.
    PubMed     Abstract available


  67. BRAUN AD, Mengoni M, Bonifatius S, Tuting T, et al
    Activated Hgf-Met signaling cooperates with oncogenic Braf to drive primary cutaneous melanomas and angiotropic lung metastases in mice.
    J Invest Dermatol. 2020 Jan 20. pii: S0022-202X(20)30019.
    PubMed     Abstract available


  68. HONG CH, Ho JC, Lee CH
    Steroid receptor RNA activator (SRA), a long noncoding RNA, activates p38, facilitates epithelial mesenchymal transformation, and experimental melanoma metastasis.
    J Invest Dermatol. 2020 Jan 13. pii: S0022-202X(19)33503.
    PubMed     Abstract available


  69. SHELLMAN MH, Shellman YG
    Human against Machine? Machine Learning Identifies MicroRNA Ratios as Biomarkers for Melanoma.
    J Invest Dermatol. 2020;140:18-20.
    PubMed     Abstract available


    December 2019
  70. CHITSAZAN A, Lambie D, Ferguson B, Handoko HY, et al
    Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi.
    J Invest Dermatol. 2019 Dec 24. pii: S0022-202X(19)33492.
    PubMed    


  71. BARCELO C, Siso P, Maiques O, Garcia-Mulero S, et al
    T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF(V600E) melanoma: TTCCs are therapy target in BRAF(V600E) melanoma.
    J Invest Dermatol. 2019 Dec 23. pii: S0022-202X(19)33497.
    PubMed     Abstract available


    November 2019
  72. LIU X, Mi J, Qin H, Li Z, et al
    E2F1/IGF-1R loop contributes to BRAF inhibitor resistance in melanoma.
    J Invest Dermatol. 2019 Nov 6. pii: S0022-202X(19)33385.
    PubMed    


    October 2019
  73. WENZINA J, Holzner S, Puujalka E, Cheng PF, et al
    Inhibition of p38/MK2 signaling prevents vascular invasion of melanoma.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)33299.
    PubMed     Abstract available


  74. ZENG H, Judson-Torres RL, Shain AH
    The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)32699.
    PubMed     Abstract available


    September 2019
  75. GIBBS DC, Orlow I, Vernali S, Powell HB, et al
    Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma.
    J Invest Dermatol. 2019 Sep 27. pii: S0022-202X(19)33239.
    PubMed    


    August 2019
  76. TORRES R, Lang UE, Hejna M, Shelton SJ, et al
    MicroRNA ratios distinguish melanomas from nevi.
    J Invest Dermatol. 2019 Aug 22. pii: S0022-202X(19)31788.
    PubMed     Abstract available


    July 2019
  77. PEI S, Chen J, Lu J, Hu S, et al
    The Long Noncoding RNA UCA1 Negatively Regulates Melanogenesis in Melanocytes.
    J Invest Dermatol. 2019 Jul 2. pii: S0022-202X(19)31848.
    PubMed     Abstract available


    March 2019
  78. TAKABE P, Karna R, Rauhala L, Tammi M, et al
    Melanocyte hyaluronan coat fragmentation enhances the UVB-induced TLR-4 receptor signaling and expression of proinflammatory mediators IL-6, IL-8, CXCL-1 and CXCL-10 via NF-kappaB activation.
    J Invest Dermatol. 2019 Mar 29. pii: S0022-202X(19)31391.
    PubMed     Abstract available


    January 2019
  79. SHIN SY, Choi JH, Jung E, Gil HN, et al
    The EGR1-STAT3 Transcription Factor Axis Regulates alpha-MSH-induced Tyrosinase Gene Transcription in Melanocytes.
    J Invest Dermatol. 2019 Jan 12. pii: S0022-202X(19)30010.
    PubMed    


  80. AVIGAD LARON E, Aamar E, Enshell-Seijffers D
    The Serine Protease Activity of Corin Is Required for Normal Pigment Type Switching.
    J Invest Dermatol. 2019;139:257-259.
    PubMed    


    July 2018
  81. ZHANG K, Anumanthan G, Scheaffer S, Cornelius LA, et al
    HMGB1/RAGE Mediates UVB-induced Secretory Inflammatory Response and Resistance to Apoptosis in Human Melanocytes.
    J Invest Dermatol. 2018 Jul 17. pii: S0022-202X(18)32348.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: